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Introduction
Poor response to ovarian stimulation for assisted repro-
ductive treatment is a therapeutic challenge. Patients
expected to be poor responders are generally of advanced
age, have a high basal follicle-stimulating hormone (FSH)
concentration, low basal inhibin B or anti-müllerian
hormone concentration, and lower antral follicle counts.
The estimated prevalence of poor responders among
patients undergoing in vitro fertilization (IVF) treatment
is 9–24% [1]. Over the years, different protocols have
been suggested to tackle this problem, but most of these
interventions have met with only limited success and the
optimum stimulation protocol for poor responders is still
unknown.
Most IVF programmers use long gonadotropin-
releasing hormone (GnRH) agonist protocols with
gonadotropins for ovarian stimulation. When the regu-
lar dose of gonadotropins (150–300 IU) fails to induce
a proper multifollicular growth, the obvious clinical
approach is to increase the dose of gonadotropins. 
A high dose of gonadotropins has been used by the vast
majority of authors in poor responder patients [2].
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SUMMARY
Objective: To evaluate the in vitro fertilization and intracytoplasmic sperm injection outcomes after high initial
doses of follicle-stimulating hormone (FSH) in patients with poor ovarian reserve.
Materials and Methods: For in vitro fertilization/intracytoplasmic sperm injection patients younger than 40 years
of age, 345 cycles were examined from April 2003 to April 2007. As a control, 218 cycles received gonadotropin-
releasing hormone agonist and regular initial doses of FSH from day 3 of the treated cycle. The remaining 
127 cycles were treated with high initial doses of FSH with an antagonist or low doses of gonadotropin-releasing
hormone because of poor ovarian reserve.
Results: When higher initial doses of FSH were used, lower estradiol levels on the day of human chorionic
gonadotropin injection and less mature oocytes were retrieved from the group with poor ovarian reserve.
Clinical pregnancy rates per embryo transfer were similar (45.7% vs. 48.2%, p = 0.686). There was a trend of lower
ongoing pregnancy rate per cycle (28.3% vs. 38.5%, p = 0.05) in the study compared with the control group. In
the subgroups with high doses of FSH, neither protocol was superior in terms of clinical (45.5% vs. 46.2%, p =0.952)
or ongoing pregnancy rates per embryo transfer (37.9% vs. 42.3%, p = 0.695).
Conclusion: There was no significant difference in clinical pregnancy rate of the two groups when good embryos
were obtained. The group with poor ovarian reserve had lower ongoing pregnancy rates per cycle. For patients with
expected poor ovarian response, treatment with high doses of FSH initially is an option. [Taiwan J Obstet Gynecol
2010;49(4):442–448]
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Several randomized control trails have demon-
strated that higher starting doses of gonadotropins do
not lead to improved pregnancy rates, despite lower
cancellation rates or whether the patients were treated
with a GnRH agonist [3,4] or antagonist protocol [5,
6]. However, patients in these trials were all expected
normal responders. In a retrospective study by Karande
[7], despite an increase in FSH doses, the numbers of
oocytes retrieved and the pregnancy rates were low. In
another retrospective study by Land et al [8], the number
of oocytes retrieved increased after doubling the human
menopausal gonadotropin (hMG) doses in low res-
ponders, but the pregnancy rates remained low. In a
prospective randomized study by Van Hooff et al [9],
increasing the starting dose up to 450 IU was ineffec-
tive in increasing ovarian response and/or in increasing
pregnancy rate. In another randomized controlled
study by Klinkert et al [10], doubling the starting doses
of gonadotropins in expected poor responders on the
basis of antral follicle counts did not lead to an improve-
ment of the response during IVF treatment. They enrolled
52 patients with the average age above 40 years. The
stimulation protocol was a long suppression protocol
with starting doses of 150 IU recombinant FSH in
Group I and 300 IU recombinant FSH in Group II.
Different protocols have also been proposed for the
management of low ovarian response in IVF. Feldberg
et al [11] compared different doses of GnRH agonist
administered over a long protocol in women with pre-
vious poor response to gonadotropins. They found a
higher estrogen concentration, more oocytes were col-
lected and fertilized, more embryos transferred, and 
a lower cancellation rate with lower doses of GnRH. 
In another randomized study [12], a lower amount of
gonadotropins were required and shorter duration for
stimulation were also found in the group with lower
doses of GnRH agonist for pituitary suppression.
A GnRH antagonist has also become available in
recent years. Because of its distinct pharmacological
mode of action, GnRH antagonist may allow for maxi-
mum response of ovaries to the stimulation of
gonadotropins without early follicular suppression.
Preliminary comparisons between the GnRH agonist
long protocol and GnRH antagonist protocol applied
in poor responders have shown a lower consumption
of gonadotropins, a shorter duration of stimulation
[13], a non-significant trend for a greater number of
oocytes retrieved and a lower cycle cancellation rate
[14] in the GnRH antagonist group. However, a meta-
analysis including five studies of fixed GnRH antago-
nist protocols compared with long agonist protocols,
indicated 5% less clinical pregnancies in the antagonist
groups [15].
The aim of our study was to evaluate the IVF/intra
cytoplasmic sperm injection (ICSI) outcomes of high
initial doses of FSH (at least 450 IU daily) in patients
with poor ovarian reserve compared with the standard
dose of FSH in IVF patients. Different methods for
pituitary suppression in the group with poor ovarian
reserve were also compared.
Materials and Methods
This study was a retrospective study of IVF/ICSI outcome
based on the medical records of patients in the fertility
unit of MacKay Memorial Hospital in Taipei, Taiwan
from April 2003 to April 2007. The study protocol was
approved by the Institutional Review Board of the
Mackay Memorial Hospital. Patients diagnosed with
systemic disease, endocrine abnormality, hydrosalpinx
or cycles for oocyte donation were excluded from the
study to minimize confounding factors. A total of 345
treated cycles were included in this study. A total of 218
cycles received the long protocol of GnRH agonist and
regular initial doses of FSH (no more than 300 IU daily)
from day 3 of the treatment cycle. The other 127 cycles
were treated with high initial doses of FSH (at least
450 IU daily) from day 3 with antagonist, or by the long
protocol with a low dose of GnRH agonist because of
poor ovarian reserve.
Ovarian stimulation protocol
Patients treated with high initial doses of FSH were
included in the study group because of cancellation of
the previous assisted reproductive technology due to
poor response and/or a total of four or less antral fol-
licles on day 3 of the menstrual cycle. The threshold of
four antral follicles of 2–5 mm was based on the study
by Tomas et al [16] in which patients with less than five
follicles measuring 2–5 mm were classified as having
inactive ovaries. Bancsi et al [17] also found the thresh-
old of no more than four antral follicles had the lowest
error rate to predict poor response.
In the study group, 95 cycles were treated by the
GnRH antagonist protocol and the other 32 cycles
were treated by the long protocol with lower dose of
leuprolide acetate (0.25 mg or 0.15 mg). In the GnRH
antagonist treated cycles, recombinant FSH (Gonal-F;
Serono Laboratories, Aubonne, Switzerland) and hMG
(Menopur; Ferring Pharmaceuticals, Denmark) were
administrated daily from the third day of the menstrual
cycle. The doses were adjusted according to the patient’s
individual ovarian response. Cetrorelix (Cetrotide;
Serono, Baxter Oncology GmbH, Halle, Germany) was
administered subcutaneously at a dose of 0.25 mg
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daily when the dominant follicle reached 14 mm in mean
diameter, until the day of human chorionic gona-
dotropin (hCG) administration. In the other 32 cycles,
leuprolide acetate (Takeda Pharma GmbH, Stolberg,
Germany) was given at a daily dose of 0.25 mg or
0.15 mg, starting on day 21 of the previous cycle. Once
serum levels of estradiol (E2) lower than 40 pg/mL
were achieved on day 3 of the stimulating cycle, recom-
binant FSH and hMG were given until the day of hCG
administration. The doses were also adjusted according
to the patient’s ovarian response. In the study group,
the initial daily doses of FSH were at least 450 IU.
In the control group, leuprolide acetate was given at
a daily dose of 0.5 mg, starting on day 21 of the previous
cycle. Once serum levels of E2 were less than 40 pg/mL
were achieved on day 3 of the stimulating cycle, recom-
binant FSH and hMG were given until the day of hCG
administration. The doses were also adjusted according
to the patient’s ovarian response. The initial daily doses
of FSH were all no more than 300 IU.
In both groups, the ovarian response was moni-
tored by serial transvaginal ultrasound scanning and by
measuring the serum E2 concentration. A dose of hCG
(10,000 IU; Pregnyl, Organon, Greece) was intramus-
cularly given for final maturation when the leading fol-
licles reached 20 mm together with at least two following
follicles that reached diameters of 18 mm as detected
on the ultrasound scan.
Oocyte retrieval was performed 34–36 hours later.
Cycles in which less than two dominant follicles devel-
oped and E2 was less than 500 pg/mL on the day of
hCG administration, or in which the ovaries failed 
to respond after stimulation, were either cancelled or
converted to intrauterine insemination in patients with
patent tubes.
ICSI was performed only in cases with male factor
infertility, which was defined by the presence of any of
the following parameters: sperm concentration less than
10 × 106/mL; motility less than 50%, normal morphol-
ogy less than 4%; or previous fertilization failure. Upon
completion of oocyte collection and IVF/ICSI, embryos
were graded morphologically on day 3 and according
to the system modified from Veeck. Embryos classified as
grade 1 or 2 were denoted as good embryos. Embryo
transfer was performed 72 hours after oocyte retrieval.
When good embryos were available to transfer, this cycle
was designated as the “cycle with embryo transfer”.
The luteal phase was supported by vaginal supple-
mentation with 200 mg micronized natural proges-
terone (Progeffik; Effik, Paris, France) three times a day
or Crinone 8% vaginal gel and daily injection of 50 mg
progesterone or hCG (2,500 IU) given every 3 days for
three doses commencing 2 days after oocyte retrieval.
To assess treatment outcome, serum hCG was mea-
sured 14 days after oocyte retrieval. If hCG had been
given as luteal phase support, a pregnancy test with
urinary hCG test would be done 18 days after oocyte
retrieval. Implantation was defined by the observation of
a gestational sac in the uterus by transvaginal ultrasono-
graphy. An ongoing pregnancy was defined by obser-
vation of a fetal heartbeat by ultrasonography after 
7 weeks of gestation. Abortion was defined as fetal
loss after the gestational sac was detected.
Statistical analysis
Statistical analysis was performed using the Statistical
Packages for Social Sciences version 12.0 (SPSS Inc.,
Chicago, IL, USA). The differences of means between
two variables were calculated using the Mann-Whitney
U test. The differences of fertilization rate, rate of
embryo transfer per cycle, implantation rate, clinical
pregnancy rate, ongoing pregnancy rate and abortion
rate were analyzed by the χ2 test or Fisher’s exact tests as
appropriate. A p value smaller than 0.05 was consid-
ered statistically significant.
Results
In total 345 cycles were analyzed, with cycle char-
acteristics and pregnancy outcomes between the two
groups compared in Table 1. Significant differences
were observed between the study and control groups
with respect to patient age (35.1 ± 3.0 years vs. 32.2 ±
3.9 years, p < 0.01), the starting doses of FSH (475.2 ±
39.1 IU vs. 234.9 ± 40.3 IU, p < 0.01), total dose of FSH
(4,566.9±1,078 IU vs. 2,314.3±627.5 IU, p <0.01), can-
cellation rate (14.1% vs. 3.2%, p<0.01), serum E2 level on
hCG injection day (1,191.9 ± 695.5 pg/mL vs. 2,714.8 ±
1,452.6 pg/mL, p < 0.01), mature follicles (4.7 ± 1.9 vs.
9.7 ± 3.9, p < 0.01) and oocytes obtained (6.8 ± 3.6 vs.
11.1 ± 5.9, p < 0.01). However, there was no significant
difference between the control and study groups in
terms of total days of stimulation (10.8 ± 2.2 vs. 10.7 ±
1.6, p < 0.01). All 18 cancelled cycles (14.1%) in the
study group were the result of insufficient ovarian re-
sponse, while only six (3.2%) cycles in the control group
were cancelled for the same reason. The remaining one
cycle cancelled in the control group was due to ovarian
hyperstimulation syndrome.
Although we saw a similar fertilization rate in both
groups (77.3% vs. 74.5%, p = 0.43), there were signifi-
cant differences between the groups in the number of
total embryos (4.4 ± 2.9 vs. 7.2 ± 4.2, p < 0.01) and good
embryos obtained (2.3±1.9 vs. 4.6±3.8, p <0.01), good
embryos to transfer (2.3 ± 1.1 vs. 2.6 ± 1.0, p < 0.05),
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and the rate of embryo transfer per cycle (72.4% vs.
89.4%, p < 0.01). There were no significant differences
in the clinical pregnancy rate per embryo transfer
(45.7% vs. 48.2%, p = 0.686), implantation rate (31.0%
vs. 27.0%, p = 0.276), abortion rate (14.3% vs. 10.6%,
p = 0.571), and ongoing pregnancy rate per embryo
transfer (39.1% vs. 43.1%, p = 0.527). A trend of higher
ongoing pregnancy rate per cycle in the control group
compared with the study group was still noted (28.3%
vs. 38.5%, p = 0.05).
To compare the treatment outcomes of high initial
doses of FSH with different protocols for pituitary sup-
pression, the 127 cycles in the study group were further
divided into the subgroups “antagonist protocol” and
“long protocol with lower doses of GnRH agonist”.
Cycle characteristics and pregnancy outcomes between
the two groups are list in Table 2. No significance dif-
ference was observed between the two groups in patient
age (35.4 ± 2.9 years vs. 34.3 ± 3.2 years, p = 0.07) and
cancellation rate (16.8% vs. 3.1%, p = 0.069). However,
with more total FSH doses used (4,804.3±1,104.7 IU vs.
3,869.5 ± 593.3 IU, p < 0.01) and longer stimulation
duration (11.1 ± 2.4 days vs. 9.9 ± 1.3 days, p < 0.01) in
the antagonist group, lower serum levels of E2 upon
hCG injection (1,089.1 ± 688.6 pg/mL vs. 1,493.9 ±
634.0 pg/mL, p < 0.01), a low number of follicles larger
than 1.4 cm (4.5 ± 1.9 vs. 5.4 ± 1.8, p < 0.05) and less
oocytes obtained (6.3 ± 3.4 vs. 8.2 ± 3.8, p < 0.05) were
observed in the antagonist group. There were no signifi-
cant differences in the fertilization rate (76.7% vs. 78.5%,
p = 0.432), numbers of total embryos (4.1 ± 2.5 vs.
5.2 ± 3.7, p = 0.186) and good embryos (2.3 ± 1.9 vs.
2.4 ± 1.9, p = 0.693), rate of embryo transfer per cycle
(69.5% vs. 81.3%, p = 0.197), numbers of good embryo
to transfer (2.2±1.1 vs. 2.5±1.1, p =0.29), implantation
rate (30.4% vs. 32.3%, p=0.782), multiple pregnancy rate
(34.4% vs. 58.3%, p = 0.417), clinical pregnancy rate per
embryo transfer (45.5% vs. 46.2%, p = 0.952), ongoing
pregnancy rate per embryo transfer (37.9% vs. 42.3%, p =
0.695) and ongoing pregnancy rate per cycle (26.3% vs.
34.4%, p = 0.382).
Discussion
Our study focused on those expected poor responders
younger than 40 years of age. A similar duration of
ovarian stimulation was found in both the study and
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Table 1. Basic characteristics and outcomes of the study and control groups*
Study group (n = 127) Control group (n = 218) p
Age (yr) 35.1 ± 3.0 32.2 ± 3.9 < 0.01
Starting daily dose of FSH (IU) 475.2 ± 39.1 234.9 ± 40.3 < 0.01
Cancel rate (%) 14.1 3.2 < 0.01
Days of stimulation 10.8 ± 2.2 10.7 ± 1.6 NS
Total FSH dose (IU) 4,566.9 ± 1,078.0 2,314.3 ± 627.5 < 0.01
Estradiol on day of hCG injection (pg/mL) 1,191.9 ± 695.5 2,714.8 ± 1,452.6 < 0.01
No. of follicles > 14 mm 4.7 ± 1.9 9.7 ± 3.9 < 0.01
No. of oocytes 6.8 ± 3.6 11.1 ± 5.9 < 0.01
No. of mature oocytes 5.8 ± 3.3 9.9 ± 5.4 < 0.01
Fertilization rate (%) 77.3 74.5 NS
IVF (%) 80.5 76.7 NS
ICSI (%) 68.3 72.0 NS
No. of total embryos 4.4 ± 2.9 7.2 ± 4.2 < 0.01
No. of good embryos 2.3 ± 1.9 4.6 ± 3.8 < 0.01
Rate of embryo transfer per cycle (%) 72.4 89.4 < 0.01
No. of good embryo to transfer 2.3 ± 1.1 2.6 ± 1.0 < 0.05
Clinical pregnancy rate per embryo transfer (%) 45.7 48.2 NS
Implantation rate (%) 31.0 27.0 NS
Abortion rate (%) 14.3 10.6 NS
Ongoing pregnancy rate per embryo transfer, n (%) 36/92 (39.1) 84/195 (43.1) NS
Ongoing pregnancy rate per cycle, n (%) 36/127 (28.3) 84/218 (38.5) 0.05
*Data are presented as mean ± standard deviation, % or n (%). FSH = follicle stimulating hormone; NS = not significant; hCG = human chorionic gonadotropin.
standard groups. Even with high starting doses of re-
combinant FSH in the study group, a higher cancellation
rate, lower serum E2 levels on the day of hCG injection
and lower numbers of oocytes obtained were still
observed in these expected poor responders. A high
initial daily dose of FSH stimulation could not com-
pensate for the poor ovarian reserve. These patients
with less ovarian reserve also had less chance for embryo
transfer in each cycle of IVF treatment because of the
higher cancellation rate, and the lower number of oocytes
and good embryos obtained.
It is noteworthy that the implantation rate and the
clinical pregnancy rate per embryo transfer were simi-
lar in the study and control groups when embryos with
good quality could be obtained. This may be because
all patients were younger than 40 years of age in both
groups, and implantation was more greatly affected by
the age and quality of embryos than the expected poor
ovarian response. With the similar implantation rate,
both groups achieved a similar clinical pregnancy rate
per embryo transfer and ongoing pregnancy rate per
embryo transfer. The abortion rate in both study and
control groups were also without significant differences.
This supports the idea that the implantation rate may
not be affected in these expected poor responders aged
younger than 40.
For patients, the ongoing pregnancy rate for each
cycle of IVF treatment is of greatest concern. In our
study, the ongoing pregnancy rate per cycle was lower
in patients with poor ovarian reserve. This could be
explained by the high cancellation rate and lower
embryo transfer rate in the study group. In addition to
looking for an egg donor, a high starting dose of recom-
binant FSH with antagonist protocol/a long protocol
with lower doses of GnRH agonist may be another
option for patients with poor ovarian reserve.
Different methods for pituitary suppression, antago-
nist protocol (Group I) and long protocol with lower
doses of GnRH agonist (Group II), in the group with high
initial doses of FSH treatment were also compared in
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Table 2. Comparison of basic characteristics and outcomes of Group I (antagonist protocol) and Group II (long protocol
with lower doses of gonadotropin-releasing hormone agonist)*
Group I (n = 95) Group II (n = 32) p
Age (yr) 35.4 ± 2.9 34.3 ± 3.2 NS
Starting dose of FSH (IU) 481.6 ± 41.8 454.7 ± 18.4 < 0.01
Cancel rate (%) 16.8 3.1 NS
Days of stimulation (d) 11.1 ± 2.4 9.9 ± 1.3 < 0.01
Total FSH dose (IU) 4,804.3 ± 1,104.7 3,869.5 ± 593.3 < 0.01
Estradiol on day of HCG injection 1,089.1 ± 688.6 1,493.9 ± 634.0 < 0.01
(pg/mL)
No. of follicles > 14 mm 4.5 ± 1.9 5.4 ± 1.8 < 0.05 
No. of oocytes 6.3 ± 3.4 8.2 ± 3.8 < 0.05
No. of mature oocytes 5.5 ± 3.1 6.7 ± 3.7 NS
Fertilization rate (%) 76.7 78.5 NS
IVF (%) 80.4 80.6 NS
ICSI (%) 67.0 71.4 NS
No. of total embryo 4.1 ± 2.5 5.2 ± 3.7 NS
No. of good embryo 2.3 ± 1.9 2.4 ± 1.9 NS
Rate of embryo transfer per cycle (%) 69.5 81.3 NS
No. of good embryo to transfer 2.2 ± 1.1 2.5 ± 1.1 NS
Clinical pregnancy rate per embryo 45.5 46.2 NS
transfer (%)
Implantation rate (%) 30.4 32.3 NS
Abortion rate (%) 16.7 8.3 NS
Ongoing pregnancy rate per embryo 37.9 42.3 NS
transfer (%)
Ongoing pregnancy rate per cycle (%) 26.3 34.4 NS
*Data are presented as mean ± standard deviation, % or n (%). NS = not significant; GnRH = gonadotropin-releasing hormone; FSH = follicle stimulating hormone.
our study. With similar average age of patients, patients
in Group I had a less favorable result of ovarian stimula-
tion (lower serum E2 on the day of hCG injection and
less oocytes obtained). This result is comparable with
previous studies [18,19] where the number of follicles
and number of oocytes retrieved in a flexible antago-
nist protocol were less favorable than in a long GnRH
agonist protocol. The rate of embryo transfer in each
cycle was higher in Group II but the difference was not
statistically significant.
The possible direct or indirect negative effect on
the endometrium of the GnRH antagonist has been
discussed [20–22]. With similar number of embryos
transferred, lower implantation and pregnancy rates
have been observed in woman undergoing ovarian
stimulation with the GnRH antagonist protocol [23].
Conversely, another recent study compared the endo-
metrial development in egg-donors treated with the
GnRH antagonist protocol, the GnRH agonist long
protocol or in natural cycles. They found more similar-
ity in the endometrial development of donors treated
with GnRH antagonist and natural cycles [24]. Our
study also demonstrated similar implantation and abor-
tion rates in Groups I and II. There were no significant
differences in the clinical and ongoing pregnancy rates
per embryo transfer when a similar number of good
embryos were transferred.
In conclusion, this study demonstrates that the
outcomes of IVF treatment in patients with expected
poor response and younger age who received high ini-
tial daily doses of FSH are still not compatible to a
normal responder. The similar implantation rate and
an acceptable ongoing pregnancy rate per embryo trans-
fer may be achieved in patients with poor ovarian re-
serve if embryos with good quality could be obtained.
However, because of the limitation of retrospective
studies and the imbalanced case numbers in the two
groups, a further study is recommended to confirm
these conclusions.
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